Efficacy News and Research

RSS

How durable is the immune response generated from the BNT162b2 vaccine?

In a recent study, researchers analyzed antibody responses to the homologous Wu strain and several other SARS-CoV-2 variants after BNT162b2 vaccination.

4 Oct 2021

mRNA vaccination induces strong humoral immune responses against SARS-CoV-2 in over 80's

A recent study assesses the serological and cellular responses to Pfizer’s BNT162b2 mRNA vaccine in people aged 80-96 years.

4 Oct 2021

Psychedelic drug changes the emotional state of people listening to music

Scientists have found that the psychedelic drug psilocybin, in development as an anti-depressive treatment, changes the emotional state of people listening to music.

4 Oct 2021

Prevalence of adaptive and prolonged infections’ mutations in receptor-binding domain of SARS-CoV-2 spike protein

A new study used the available nucleotide sequence data on the NCBI COVID-19 database and estimated the global prevalence of adaptive and prolonged infections' mutations in the RBD of the S protein.

4 Oct 2021

Difficulties of stability and storage of mRNA COVID-19 vaccines

Two researchers have collaborated to review the difficulties faced in storing and transporting these vaccines in a manner that will keep them stable.

4 Oct 2021

REGEN-COV shown to reduce risk of COVID-19–related hospitalization or death from any cause

The phase 1-2 clinical trials conducted using REGEN-COV had shown promising therapeutic benefits in COVID-19 outpatients. Its effect was further investigated in the present phase 3 clinical trial, the findings of which have been published in the "The New England Journal of Medicine".

3 Oct 2021

Immune response to SARS-CoV-2 variants of concern after natural infection or vaccination

A recent review paper published in the MDPI's journal Viruses highlights how available vaccines may be effective in protecting individuals against severe forms of coronavirus disease 2019 (COVID-19), but the protection against infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its transmission to others may be reduced – with consequences for community protection and herd immunity.

3 Oct 2021

Dispensing of hydroxychloroquine and ivermectin in Australia jumped in first year of COVID

A new study describes the nature and extent of the shift in dispensing these medications, as well as its eventual outcome.

3 Oct 2021

Non-pharmaceutical interventions effectively reduce COVID case burden in the United States

A new study analyzes the impact of non-pharmaceutical interventions in the United States against SARS-CoV-2 transmission.

3 Oct 2021

Providing better mental health treatment for adolescents with disabilities

Many teens with intellectual and developmental disabilities receive care coordination services from a Maternal and Child Health Bureau-funded state agency.

2 Oct 2021

WHO's new List of Essential Medicines prioritizes access to diabetes and cancer treatments

WHO today published the new edition of its Model Lists of Essential Medicines and Essential Medicines for Children, which include new treatments for various cancers, insulin analogues and new oral medicines for diabetes, new medicines to assist people who want to stop smoking, and new antimicrobials to treat serious bacterial and fungal infections.

1 Oct 2021

UVA researchers identify 14 genes that cause obesity

Promising news in the effort to develop drugs to treat obesity: University of Virginia scientists have identified 14 genes that can cause and three that can prevent weight gain. The findings pave the way for treatments to combat a health problem that affects more than 40% of American adults.

1 Oct 2021

Two-mAb cocktail prevents SARS-CoV-2 infection, study suggests

A promising study shows that a combination of two monoclonal antibodies effectively neutralized SARS-CoV-2 in monkeys and proved efficacious against newer variants of concern in vitro.

1 Oct 2021

Enveloped virus-like particle based vaccines potentially broaden immunity against SARS-CoV-2 variants

A new preprint describes promising results with a novel vaccine candidate designed to improve the breadth of neutralization.

1 Oct 2021

Structure of monoclonal antibody that can potently neutralize SARS-CoV-2 and variants of concern

A new preprint deals with the analysis of the monoclonal antibody J08, which was capable of powerful neutralization of the wildtype SARS-CoV-2, and its VOCs.

1 Oct 2021

Persistence of humoral immune response in SARS-CoV-2 convalescent individuals a year after infection

A new study reported the persistence of immune responses over twelve months after natural infection.

1 Oct 2021

Novel Assay Platform for 3D Microfluidic Cancer Research

AMSBIO have supplied custom Chimeric antigen receptor (CAR)-T products to the University of Strathclyde (UoS) in Glasgow, UK, and ScreenIn3D Ltd, allowing them to perform novel immune-oncology assays in 3D microfluidic cancer models.

From AMS Biotechnology 1 Oct 2021

Portable PDT device could pave the way for at-home treatment of basal cell carcinoma

A new prototype photodynamic therapy (PDT) device that can be used at home significantly reduces pain levels during treatment of basal cell carcinoma (BCC), while achieving efficacy comparable with a hospital stay. These findings come from a breakthrough pilot study, presented today at the 30th EADV Congress.

1 Oct 2021

Research finds possible connection between bacteria and bowel cancer

New research from RCSI University of Medicine and Health Sciences has found a possible relationship between the presence of a specific type of bacteria found in tumors and the spread of bowel cancer.

1 Oct 2021

Comparison of Pfizer, Moderna, J&J, AZ vaccines for neutralization titer, against Delta and other variants

Is one COVID vaccine better than the other? Four current vaccines — Moderna, Pfizer-BioNTech, Johnson & Johnson, and AstraZeneca — are highly effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but a new medRxiv* study suggests the level of protection varies.

30 Sep 2021

Efficacy News and Research

How durable is the immune response generated from the BNT162b2 vaccine?

mRNA vaccination induces strong humoral immune responses against SARS-CoV-2 in over 80's

Psychedelic drug changes the emotional state of people listening to music

Prevalence of adaptive and prolonged infections’ mutations in receptor-binding domain of SARS-CoV-2 spike protein

Difficulties of stability and storage of mRNA COVID-19 vaccines

REGEN-COV shown to reduce risk of COVID-19–related hospitalization or death from any cause

Immune response to SARS-CoV-2 variants of concern after natural infection or vaccination

Dispensing of hydroxychloroquine and ivermectin in Australia jumped in first year of COVID

Non-pharmaceutical interventions effectively reduce COVID case burden in the United States

Providing better mental health treatment for adolescents with disabilities

WHO's new List of Essential Medicines prioritizes access to diabetes and cancer treatments

UVA researchers identify 14 genes that cause obesity

Two-mAb cocktail prevents SARS-CoV-2 infection, study suggests

Enveloped virus-like particle based vaccines potentially broaden immunity against SARS-CoV-2 variants

Structure of monoclonal antibody that can potently neutralize SARS-CoV-2 and variants of concern

Persistence of humoral immune response in SARS-CoV-2 convalescent individuals a year after infection

Novel Assay Platform for 3D Microfluidic Cancer Research

Portable PDT device could pave the way for at-home treatment of basal cell carcinoma

Research finds possible connection between bacteria and bowel cancer

Comparison of Pfizer, Moderna, J&J, AZ vaccines for neutralization titer, against Delta and other variants

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News